Avacta sells veterinary division to Vimian for up to GBP2.3 million
(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.
Read moreWed, 10th Oct 2018 16:33
(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.
Read moreAvacta shares up 12% after chemotherapy drug advances to next stage
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.
Read moreAvacta selects potential tumour treatment for preclinical development
Read moreAIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers
Read moreLONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony
Read moreAbingdon Health plunges after Avacta stops selling Covid-19 test
Read moreAIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
Read more(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.
Read moreAvacta shares drop as Covid tests show reduced sensitivity to Omicron
Read moreLONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures
Read moreAIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins
Read moreAvacta shares up as flow tests receive CE mark for self-test use
Read moreAvacta confirms lateral flow tests can detect Omicron variant
Read more